Researcher
Jurgen Joossens
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Tech Transfer Office (TTO) (Research group)
Responsible
From1 Nov 2016 → Today - Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2005 → 31 Oct 2016
Projects
1 - 10 of 22
- SkillsApp, market exploration and validation of innovative web application to objectify skills evaluation.From1 May 2024 → TodayFunding: IOF - technology validation in lab
- AI-driven optimalisation of the user experience (UX) of digital tools.From1 Sep 2023 → TodayFunding: IOF - technology concept exploration
- CremAN: Simulating Input/Output and CAN communication for testing remanufactured automotive parts.From1 May 2023 → TodayFunding: IOF - technology concept exploration
- Optimization of the cryopreservation procedure of cells for therapeutic and research applications using Design of Experiments.From1 Jan 2023 → 31 Dec 2023Funding: IOF - technology concept exploration
- IOF Alliance Valorisation Manager UAntwerpen - UZAFrom7 Nov 2022 → TodayFunding: IOF - mandates
- IOF Valorisation Life SciencesFrom7 Mar 2022 → TodayFunding: IOF - mandates
- Development of a cascading approach for zero-waste valorization of agricultural and food residues.From1 Dec 2021 → 30 Nov 2023Funding: IOF - technology concept exploration
- IOF Valorisation - Project DevelopmentFrom1 Jul 2021 → TodayFunding: IOF - mandates
- Towards integrated Practices of Schools, Reception Centres and Leisure Time Facilities for Refugee Children: an Action Research.From1 May 2021 → 30 Apr 2023Funding: IOF - technology concept exploration
- IOF Valorisation of social and human sciences.From1 Mar 2021 → TodayFunding: IOF - mandates
Publications
21 - 30 of 50
- In vivo amyloid-$\beta$ imaging in the APPPS1-21 transgenic mouse model with a 89Zr- labeled monoclonal antibody(2016)
Authors: Ann-Marie Waldron, Jens Fissers, Annemie Van Eetveldt, Bianca Van Broeck, Marc Mercken, Darrel J. Pemberton, Pieter Van Der Veken, Koen Augustyns, Jurgen Joossens, Sigrid Stroobants, et al.
Pages: 1 - 12 - Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome(2016)
Authors: Hannah Ceuleers, Hanne Van Spaendonk, Nikita Hanning, Leen Heirbaut, Anne-Marie Lambeir, Jurgen Joossens, Koen Augustyns, Joris De Man, Ingrid De Meester, Benedicte De Winter
Pages: 10275 - 10286 - Novel ferroptosis inhibitors with improved potency and ADME properties(2016)
Authors: Sam Hofmans, Tom Vanden Berghe, Lars Devisscher, Behrouz Hassannia, Sophie Lyssens, Jurgen Joossens, Pieter Van Der Veken, Peter Vandenabeele, Koen Augustyns
Pages: 2041 - 2053 - Optimization and validation of an existing, surgical and robust dry eye rat model for the evaluation of therapeutic compounds(2016)
Authors: Cedric Joossen, Ellen Lanckacker, Nadia Zakaria, Carina Koppen, Jurgen Joossens, Nathalie Cools, Ingrid De Meester, Anne-Marie Lambeir, Peter Delputte, Louis Maes, et al.
Pages: 172 - 178 - Probing for improved selectivity with dipeptide-derived inhibitors of dipeptidyl peptidases 8 and 9(2016)
Authors: Leen Heirbaut, Sebastiaan van Goethem, Koen Jansen, Hans De Winter, Nicole Lamoen, Jurgen Joossens, Jonathan Cheng, Xin Chen, Anne-Marie Lambeir, Ingrid De Meester, et al.
Pages: 433 - 438 - Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay(2016)
Authors: Matthias Cleenewerck, Mandy Grootaert, Rafaela Gladysz, Yves Adriaenssens, Ria Roelandt, Jurgen Joossens, Anne-Marie Lambeir, Guido De Meyer, Wim Declercq, Koen Augustyns, et al.
Pages: 631 - 638 - Synthesis and evaluation of a Zr-89-labeled monoclonal antibody for immuno-PET imaging of amyloid-$\beta$ deposition in the brain(2016)
Authors: Jens Fissers, Ann-Marie Waldron, Thomas De Vijlder, Bianca Van Broeck, Darrel J. Pemberton, Marc Mercken, Pieter Van Der Veken, Jurgen Joossens, Koen Augustyns, Stefanie Dedeurwaerdere, et al.
Pages: 598 - 605 - Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition(2016)
Authors: Oksana Ryabtsova, Jurgen Joossens, Pieter Van Der Veken, Wim Vanden Berghe, Koen Augustyns, Hans De Winter
Pages: 5032 - 5038 - The effect of a potent tryptase inhibitor and a new serine protease inhibitor on visceral pain in a rat model of acute colitis(2015)
Authors: Hannah Ceuleers, Joris De Man, Annemie Deiteren, Heiko De Schepper, Jurgen Joossens, Sven Francque, Ingrid De Meester, Benedicte De Winter
Pages: 22 - 24 - Discovery and SAR of novel and selective inhibitors of urokinase plasminogen activator (uPA) with an imidazo[1,2-a]pyridine scaffold(2015)
Authors: Rafaela Gladysz, Yves Adriaenssens, Hans De Winter, Jurgen Joossens, Koen Augustyns, Pieter Van Der Veken
Pages: 9238 - 9257
Patents
1 - 10 of 10
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- Triazines with suitable spacers for treatment and/or prevention of HIV infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)